Science & Enterprise subscription

Follow us on Twitter

  • Then "Day at the Races"
    about 13 hours ago
  • The Forward, America’s Leading Jewish News Organization, Goes All Digital. Third-generation subscriber here and wor…
    about 15 hours ago
  • Our friends at Statista reported on a survey on how the shutdown is affecting people in the U.S., this weekend's in…
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Americans Affected by Gov’t Shutdown #Science #Business
    about 18 hours ago
  • New contributed post on Science and Enterprise: Hands Off! Robots in Modern Medicine
    about 19 hours ago

Please share Science & Enterprise

Follow by Email
Visit Us

Study Computes Cardiac Device Infection Mortality, Costs

Transplant surgery (NIH)

(National Institutes of Health)

A review of Medicare records shows that surgical infections associated with pacemakers and defibrillators led to longer hospital stays, higher mortalities, and increased hospitalization costs compared to implantations without infections. Results of the study, funded by medical device developer TYRX Inc. in Monmouth Junction, New Jersey, were presented yesterday at a meeting of the American College of Cardiology.

The research team from the Mayo Clinic, The Johns Hopkins School of Medicine, and TYRX Inc. studied the records of 200,000 Medicare beneficiaries who received pacemaker and defibrillator implantations. TYRX, Inc. develops implantable devices that combine drugs and devices focusing on infection control.

Their findings show in-hospital mortality rate for pacemaker and defibrillator implantation admissions with an infection was 8 to 11 times the rate for non-infected admissions, depending on the device type. And the longer term mortality rate — defined as the rate of death among those who developed infections during the admission quarter and following year — was 27 to 36 percent, about twice the rate of those without infection, depending on the device type.

The study shows the average length of stay in hospital among patients with infections was three times the length of stay of those without infection. Moreover the length of stay was substantially longer than the average stay for Medicare beneficiary admissions for the five leading principal diagnostic classifications: heart disease, pneumonia, malignant neoplasm, cerebrovascular disease, and fractures at all sites.

The findings indicate that total average hospitalization costs for pacemaker and defibrillator patients with an infection ranged from 55 to 118 percent higher than for those without infection, depending on the type of device. Additional costs, on average, for treating the infection ran from $17,000 per pacemaker infections to $25,600 for some defibrillators. The analysis also shows that the cost of managing the most extreme situations exceeded $1 million.

Read more: Heart Disease Treatment Cost Expected to Triple by 2030

*     *     *


Please share Science & Enterprise ...

2 comments to Study Computes Cardiac Device Infection Mortality, Costs